- Home
- APLT vs ELA Comparison
APLT vs ELA Comparison
Compare APLT & ELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- ELA
- Stock Information
- Founded
- APLT 2016
- ELA 1965
- Country
- APLT United States
- ELA United States
- Employees
- APLT N/A
- ELA N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- ELA Consumer Specialties
- Sector
- APLT Health Care
- ELA Consumer Discretionary
- Exchange
- APLT Nasdaq
- ELA Nasdaq
- Market Cap
- APLT 178.6M
- ELA 197.1M
- IPO Year
- APLT 2019
- ELA N/A
- Fundamental
- Price
- APLT $1.30
- ELA $9.31
- Analyst Decision
- APLT Buy
- ELA Strong Buy
- Analyst Count
- APLT 5
- ELA 1
- Target Price
- APLT $4.13
- ELA $9.00
- AVG Volume (30 Days)
- APLT 5.5M
- ELA 49.4K
- Earning Date
- APLT 11-10-2025
- ELA 11-05-2025
- Dividend Yield
- APLT N/A
- ELA N/A
- EPS Growth
- APLT N/A
- ELA 34.09
- EPS
- APLT N/A
- ELA 0.33
- Revenue
- APLT $121,000.00
- ELA $198,354,109.00
- Revenue This Year
- APLT N/A
- ELA $14.43
- Revenue Next Year
- APLT $5,935.35
- ELA $2.60
- P/E Ratio
- APLT N/A
- ELA $28.39
- Revenue Growth
- APLT N/A
- ELA 24.35
- 52 Week Low
- APLT $0.30
- ELA $5.10
- 52 Week High
- APLT $10.62
- ELA $9.32
- Technical
- Relative Strength Index (RSI)
- APLT 62.38
- ELA 77.68
- Support Level
- APLT $1.16
- ELA $7.61
- Resistance Level
- APLT $1.50
- ELA $7.91
- Average True Range (ATR)
- APLT 0.15
- ELA 0.32
- MACD
- APLT -0.01
- ELA 0.12
- Stochastic Oscillator
- APLT 66.64
- ELA 99.50
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About ELA Envela Corporation
Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. These include re-commercializing luxury hard assets, consumer electronics and IT equipment; and end-of-life recycling solutions. It operates through two segments, Consumer, and Commercial Services. The Consumer segment which generates key revenue for the company predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.